Showcases Stock ranks

Bristol-Myers Squibb Company (BMY)
50.88 -3.42 (-6.3%) 10-22 16:01
Open: 51.25 Pre. Close: 54.3
High: 51.9 Low: 50.51
Volume: 24,632,340 Market Cap: 83030M
Share on Facebook   Tweet this page   Tweet this page
Price Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 52.011 - 52.323 52.323 - 52.555
Low: 49.768 - 50.18 50.18 - 50.486
Close: 50.329 - 50.937 50.937 - 51.389
Stock Technical Analysis
Target: Six months: 68.51
One year: 74.39
Support: Support1: 50.51
Support2: 42.02
Resistance: Resistance1: 58.66
Resistance2: 63.69
Pivot: 59.17
Moving Averages: MA(5): 55.58
MA(20): 59.86
MA(100): 58.17
MA(250): 59.66
MACD: MACD(12,26): -1.76
Signal(12,26,9): -0.73
%K %D: %K(14,3): 2.11
%D(3): 10.43
RSI: RSI(14): 19.46
52-Week: High: 70.05
Low: 49.96
Change(%): -20.1
Average Vol(K): 3-Month: 615424
10-Days: 1111370
Price, MAs and Bollinger Bands
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.

BMY has closed below the lower band by 8.1%. If price is in a downtrend band; this downward trend in price might continue. However a short term pullback inside the band is likely. Bollinger Bands are 349.8% wider than normal. The large width of the bands suggest high volatility as compared to BMY's normal range. The bands have been in this wide range for 7 bars. This is a sign that the current trend might continue.
Stock chart
Stock News
AVEO down 4% on mid-stage tivozanib data in kidney cancer

Bristol-Myers Squibb down 3% premarket on diminished prospects of overtaking Merck in first-line lung cancer

Mirati down 29% premarket on disappointing mid-stage sitravatinib data

Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Results in Significantly Longer Treatment-Free Survival in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits in Patients with Advanced Melanoma

Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer

Financial Analysis
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Sector:  Healthcare
Industry:  Drug Manufacturers - Major
Shares Out. (M) 1631.88
Shares Float (M) 1625.64
% Held by Insiders 0.40
% Held by Institutions 75.60
Shares Short (K) 13501
Shares Short Prior Month (K)
Stock Financials
EPS 3.380
EPS Est. Current Year 3.000
EPS Est. Next Year 3.230
EPS Est. Next Quarter 0.790
Forward EPS 3.720
Book Value (p.s.) 7.420
PEG Ratio 1.39
Profit Margin -2.92
Operating Margin 26.12
Return on Assets (ttm) 1.1
Return on Equity (ttm) 2.8
Qtrly Rev. Growth 10.9
Gross Profit (p.s.) 4.570
Sales Per Share
EBITDA (p.s.) 1.449
Qtrly Earnings Growth -59.30
Operating Cash Flow (M) 5060.00
Levered Free Cash Flow (M) 3460.00
Stock Valuation
P/E 15.05
P/E Growth Ratio -0.06
P/BV 6.86
P/S 6276919296.00
P/CF 16.41
Dividend Yield 0.06
Dividends & Splits
Dividend 2.947
Dividend Pay Date 2018-11-01
Ex-Dividend Date 2018-10-04
Forward Dividend 1.600
Last Split Date
Last Split Ratio -1e+010

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator